Approval
FDA approves Bayer's asundexian, the first factor XIa inhibitor, to prevent repeat stroke
Sunharbo 50 mg, taken with antiplatelet therapy, is now approved for adults who recently had a non-cardioembolic ischemic stroke or a high-risk TIA. In the Phase 3 OCEANIC-STROKE trial, adding it cut ischemic stroke by 26% compared with antiplatelets alone, and major bleeding rates were reported as similar. China also approved the drug recently.
Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.
